Chevy Chase Trust Holdings LLC Purchases 22,821 Shares of Hologic, Inc. (NASDAQ:HOLX)

Chevy Chase Trust Holdings LLC lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 13.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 186,891 shares of the medical equipment provider’s stock after purchasing an additional 22,821 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in Hologic were worth $15,224,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Paloma Partners Management Co bought a new stake in shares of Hologic during the third quarter worth about $582,000. Erste Asset Management GmbH bought a new stake in Hologic in the third quarter valued at approximately $2,223,000. Hantz Financial Services Inc. boosted its holdings in Hologic by 1.3% in the third quarter. Hantz Financial Services Inc. now owns 105,151 shares of the medical equipment provider’s stock valued at $8,566,000 after acquiring an additional 1,357 shares during the last quarter. Public Sector Pension Investment Board boosted its holdings in Hologic by 13.7% in the third quarter. Public Sector Pension Investment Board now owns 9,959 shares of the medical equipment provider’s stock valued at $811,000 after acquiring an additional 1,200 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Hologic by 0.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,971,617 shares of the medical equipment provider’s stock valued at $160,608,000 after acquiring an additional 16,057 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and reduced their target price for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Raymond James upped their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, October 15th. Finally, JPMorgan Chase & Co. boosted their price target on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $76.87 on Thursday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a twelve month low of $67.59 and a twelve month high of $84.67. The stock’s 50 day moving average is $80.06 and its 200-day moving average is $78.54. The firm has a market capitalization of $17.44 billion, a price-to-earnings ratio of 23.26, a PEG ratio of 2.49 and a beta of 0.96.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.89 earnings per share. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.